Literature DB >> 2564230

Serum selenium levels in patients with malignant melanoma.

U Reinhold1, H Biltz, W Bayer, K H Schmidt.   

Abstract

The incidence of malignant melanoma of the skin has increased rapidly among white people during the last decade. Although the pathogenesis of malignant melanoma is not clear, epidemiologic data and experimental work indicates that ultraviolet (UV) radiation plays a critical role in tumorigenesis. Recent data implicate peroxidative reactions in UV-carcinogenesis and clearly demonstrate that selenium (Se) confers protection, in part by inducing cellular-free radical scavenging systems and by enhancing peroxide breakdown, thus enhancing the capacity of the cell to cope with oxidant stress. With this in mind, we investigated the Se status of 101 patients with malignant melanoma. Our study revealed significantly lower Se levels in the sera of melanoma patients than of controls. Although patients in all clinical stages had lower Se levels than the controls, patients in stage III (disseminated melanoma) had the lowest levels. Separate analysis of histogenetic subtypes of melanoma revealed that lentigo maligna melanoma (LMM) and superficial spreading melanoma (SSM) had the strongest association with depressed Se serum levels. Our results, showing for the first time that malignant melanoma is associated with low Se concentrations, are consistent with results of epidemiologic studies showing an inverse correlation between serum Se levels and certain cancers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564230

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

1.  Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.

Authors:  Natalie Nguyen; Arati Sharma; Nhung Nguyen; Arun K Sharma; Dhimant Desai; Sung Jin Huh; Shantu Amin; Craig Meyers; Gavin P Robertson
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-19

2.  Melanoma prevention using topical PBISe.

Authors:  Chin-Ying Chung; SubbaRao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-02

Review 3.  Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.

Authors:  C A Elstad; G G Meadows; R M Abdallah
Journal:  Clin Exp Metastasis       Date:  1990 Sep-Oct       Impact factor: 5.150

4.  Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.

Authors:  Dhimant Desai; SubbaRao V Madhunapantula; Krishnegowda Gowdahalli; Arati Sharma; Raghavendragowda Chandagaludoreswamy; Karam El-Bayoumy; Gavin P Robertson; Shantu Amin
Journal:  Bioorg Med Chem Lett       Date:  2009-09-22       Impact factor: 2.823

Review 5.  First review on the selenium status in Germany covering the last 50 years and on the selenium content of selected food items.

Authors:  Marina Liaskos; Nicole Fark; Paola Ferrario; Ann Katrin Engelbert; Benedikt Merz; Bernd Hartmann; Bernhard Watzl
Journal:  Eur J Nutr       Date:  2022-09-09       Impact factor: 4.865

6.  Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Authors:  Arati Sharma; Arun K Sharma; Subbarao V Madhunapantula; Dhimant Desai; Sung Jin Huh; Paul Mosca; Shantu Amin; Gavin P Robertson
Journal:  Clin Cancer Res       Date:  2009-02-10       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.